vs
PROGRESS SOFTWARE CORP（PRGS）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是PROGRESS SOFTWARE CORP的1.2倍（$311.4M vs $252.7M），Bio-Techne净利率更高（16.4% vs 10.2%，领先6.2%），PROGRESS SOFTWARE CORP同比增速更快（17.5% vs -1.5%），过去两年PROGRESS SOFTWARE CORP的营收复合增速更高（17.0% vs 1.3%）
Progress Software是全球领先的企业级软件服务商，主营应用开发平台、数据连接工具、数字体验解决方案等产品，服务覆盖金融、医疗、制造、零售等多行业的全球企业客户，助力客户搭建高性能可扩展的业务应用，提升运营效率。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
PRGS vs TECH — 直观对比
营收规模更大
TECH
是对方的1.2倍
$252.7M
营收增速更快
PRGS
高出19.0%
-1.5%
净利率更高
TECH
高出6.2%
10.2%
两年增速更快
PRGS
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $252.7M | $311.4M |
| 净利润 | $25.7M | $51.0M |
| 毛利率 | 81.6% | 66.9% |
| 营业利润率 | 15.2% | 24.2% |
| 净利率 | 10.2% | 16.4% |
| 营收同比 | 17.5% | -1.5% |
| 净利润同比 | 2144.6% | 126.0% |
| 每股收益（稀释后） | $0.59 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGSTECH
| Q1 26 | — | $311.4M | ||
| Q4 25 | $252.7M | $295.9M | ||
| Q3 25 | $249.8M | — | ||
| Q2 25 | $237.4M | $317.0M | ||
| Q1 25 | $238.0M | $316.2M | ||
| Q4 24 | $215.0M | $297.0M | ||
| Q3 24 | $178.7M | $289.5M | ||
| Q2 24 | $175.1M | $306.1M |
净利润PRGSTECH
| Q1 26 | — | $51.0M | ||
| Q4 25 | $25.7M | $38.0M | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $17.0M | $-17.7M | ||
| Q1 25 | $10.9M | $22.6M | ||
| Q4 24 | $1.1M | $34.9M | ||
| Q3 24 | $28.5M | $33.6M | ||
| Q2 24 | $16.2M | $40.6M |
毛利率PRGSTECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | 81.6% | 64.6% | ||
| Q3 25 | 81.0% | — | ||
| Q2 25 | 80.1% | 62.7% | ||
| Q1 25 | 80.6% | 67.9% | ||
| Q4 24 | 83.0% | 65.3% | ||
| Q3 24 | 83.7% | 63.2% | ||
| Q2 24 | 81.7% | 66.4% |
营业利润率PRGSTECH
| Q1 26 | — | 24.2% | ||
| Q4 25 | 15.2% | 18.4% | ||
| Q3 25 | 17.6% | — | ||
| Q2 25 | 16.3% | -7.5% | ||
| Q1 25 | 13.6% | 12.2% | ||
| Q4 24 | 10.0% | 16.0% | ||
| Q3 24 | 22.6% | 13.8% | ||
| Q2 24 | 15.5% | 15.0% |
净利率PRGSTECH
| Q1 26 | — | 16.4% | ||
| Q4 25 | 10.2% | 12.8% | ||
| Q3 25 | 7.8% | — | ||
| Q2 25 | 7.2% | -5.6% | ||
| Q1 25 | 4.6% | 7.1% | ||
| Q4 24 | 0.5% | 11.7% | ||
| Q3 24 | 15.9% | 11.6% | ||
| Q2 24 | 9.2% | 13.3% |
每股收益（稀释后）PRGSTECH
| Q1 26 | — | $0.32 | ||
| Q4 25 | $0.59 | $0.24 | ||
| Q3 25 | $0.44 | — | ||
| Q2 25 | $0.39 | $-0.11 | ||
| Q1 25 | $0.24 | $0.14 | ||
| Q4 24 | $0.01 | $0.22 | ||
| Q3 24 | $0.65 | $0.21 | ||
| Q2 24 | $0.37 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $94.8M | $209.8M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $478.3M | $2.1B |
| 总资产 | $2.5B | $2.6B |
| 负债/权益比越低杠杆越低 | 2.93× | — |
8季度趋势，按日历期对齐
现金及短期投资PRGSTECH
| Q1 26 | — | $209.8M | ||
| Q4 25 | $94.8M | $172.9M | ||
| Q3 25 | $99.0M | — | ||
| Q2 25 | $102.0M | $162.2M | ||
| Q1 25 | $124.2M | $140.7M | ||
| Q4 24 | $118.1M | $177.5M | ||
| Q3 24 | $232.7M | $187.5M | ||
| Q2 24 | $190.4M | $152.9M |
总债务PRGSTECH
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $260.0M | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.5B | $346.0M | ||
| Q1 25 | $1.5B | $330.0M | ||
| Q4 24 | $1.5B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
股东权益PRGSTECH
| Q1 26 | — | $2.1B | ||
| Q4 25 | $478.3M | $2.0B | ||
| Q3 25 | $477.7M | — | ||
| Q2 25 | $452.7M | $1.9B | ||
| Q1 25 | $431.8M | $2.0B | ||
| Q4 24 | $438.8M | $2.1B | ||
| Q3 24 | $425.6M | $2.1B | ||
| Q2 24 | $401.7M | $2.1B |
总资产PRGSTECH
| Q1 26 | — | $2.6B | ||
| Q4 25 | $2.5B | $2.5B | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | $2.6B | ||
| Q1 25 | $2.5B | $2.6B | ||
| Q4 24 | $2.5B | $2.7B | ||
| Q3 24 | $1.6B | $2.7B | ||
| Q2 24 | $1.6B | $2.7B |
负债/权益比PRGSTECH
| Q1 26 | — | — | ||
| Q4 25 | 2.93× | 0.13× | ||
| Q3 25 | 2.97× | — | ||
| Q2 25 | 3.22× | 0.18× | ||
| Q1 25 | 3.50× | 0.16× | ||
| Q4 24 | 3.48× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.8M | — |
| 自由现金流经营现金流 - 资本支出 | $59.9M | — |
| 自由现金流率自由现金流/营收 | 23.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 2.44× | — |
| 过去12个月自由现金流最近4个季度 | $229.5M | — |
8季度趋势，按日历期对齐
经营现金流PRGSTECH
| Q1 26 | — | — | ||
| Q4 25 | $62.8M | — | ||
| Q3 25 | $73.4M | — | ||
| Q2 25 | $30.0M | $98.2M | ||
| Q1 25 | $68.9M | $41.1M | ||
| Q4 24 | $19.7M | $84.3M | ||
| Q3 24 | $57.7M | $63.9M | ||
| Q2 24 | $63.7M | $75.5M |
自由现金流PRGSTECH
| Q1 26 | — | — | ||
| Q4 25 | $59.9M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | $29.5M | $93.3M | ||
| Q1 25 | $67.7M | $31.0M | ||
| Q4 24 | $16.8M | $77.5M | ||
| Q3 24 | $56.6M | $54.7M | ||
| Q2 24 | $62.7M | $57.5M |
自由现金流率PRGSTECH
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | — | ||
| Q3 25 | 29.0% | — | ||
| Q2 25 | 12.4% | 29.4% | ||
| Q1 25 | 28.4% | 9.8% | ||
| Q4 24 | 7.8% | 26.1% | ||
| Q3 24 | 31.7% | 18.9% | ||
| Q2 24 | 35.8% | 18.8% |
资本支出强度PRGSTECH
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.2% | 1.5% | ||
| Q1 25 | 0.5% | 3.2% | ||
| Q4 24 | 1.3% | 2.3% | ||
| Q3 24 | 0.6% | 3.2% | ||
| Q2 24 | 0.5% | 5.9% |
现金转化率PRGSTECH
| Q1 26 | — | — | ||
| Q4 25 | 2.44× | — | ||
| Q3 25 | 3.78× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 6.30× | 1.82× | ||
| Q4 24 | 17.13× | 2.42× | ||
| Q3 24 | 2.03× | 1.90× | ||
| Q2 24 | 3.93× | 1.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
